The North America Cancer Vaccines Market is expected to grow with a CAGR of 12.2% in the forecast period. The key factors propelling the growth of the market are the increasing number of cancer cases, rising investments and government funding in the development of cancer vaccines, and technological developments in cancer vaccines.
The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. According to the American Cancer Society, cancer is the leading cause of death in Canada and the second-leading cause, in the United States. Around 1.9 million new cancer cases and 693,000 cancer deaths were recorded in Northern America in 2018. The number is estimated to increase in the coming years due to the changing lifestyle of the people found in the region. Therefore with the increasing prevalence of cancer, the market is expected to grow.
Key Market Trends
Preventive Vaccines are Expected to a Hold Significant Market Share in the Treatment Method
Preventive vaccines or prophylactic vaccines are the vaccines intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. These vaccines are similar to traditional vaccines that help prevent infectious diseases, such as polio and measles, by protecting the body against infections. Most of the preventive vaccines stimulate the production of antibodies, which bind to specifically targeted microbes and block their ability to cause infection.
For instance, the HPV vaccine protects against the types of HPV that most often cause cancers. According to the Centers for Disease Control and Prevention, 2019, HPV vaccines are recommended for teenagers to prevent HPV related cancers. Moreover, the demand for these vaccines is expected to increase due to the rising incidence of cancer in North America.
The North America Cancer Vaccines Market is s highly competitive and consists of a few major players. Companies, like, Bristol-Myers Squibb, Amgen Inc, GlaxoSmithKline, Merck & Co. Inc., OSE Immunotherapeutics, Sanofi, among others, hold substantial shares in the cancer vaccines market.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Number of Cancer Cases
4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
4.2.3 Technological Developments in Cancer Vaccines
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
4.3.2 Presence of Alternative Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Recombinant Cancer Vaccines
5.1.2 Whole-cell Cancer Vaccines
5.1.3 Viral Vector and DNA Cancer Vaccines
5.1.4 Other Technologies
5.2 By Treatment Method
5.2.1 Preventive Vaccine
5.2.2 Therapeutic Vaccine
5.3 By Application
5.3.1 Prostate Cancer
5.3.2 Cervical Cancer
5.3.3 Other Applications
5.4.1 North America
184.108.40.206 United States
6.1.1 Astellas Pharma Inc.
6.1.2 Merck & Co. Inc.
6.1.3 GlaxoSmithKline PLC
6.1.4 Bristol-Myers Squibb
6.1.6 Aduro BioTech Inc.
6.1.7 Sanofi SA
6.1.8 Amgen Inc.